Pluri (PLUR) - הכנסות החברה

Pluri Inc. is actively driving innovation in biomedicine and the creation of eco-products. This expansion is based on the broader application of 3D cell structures and B2B partnerships. The company's product realization illustrates financial stability, where the 0.00 metric reflects current dynamics. Ultimately, proprietary biotechnologies enable the brand to scale the production of pharmaceuticals and cultivated meat for the global market.

Sales measure the total volume of products sold, reflecting the business's fundamental ability to generate cash flow. Analyzing this metric allows for the separation of sustainable operational growth from short-term market fluctuations. By studying the dynamics of consolidated sales, an investor assesses market capitalization through the lens of actual revenue. For Pluri Inc. (PLUR), the absence of commercial products makes this indicator a marker of dependence on external financing rather than market demand.